Clinical Trial Details

A Phase IB, Open-label, Multicenter Study to Evaluate the Safety and Preliminary Efficacy of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects

Categories (click each to see list of all clinical trials associated with that category): FPBCC CTO Studies, Myeloma/Plasma Cell Dyscrasia (ONC)

Current Status: Open

Phase: I

Principal Investigator: Wildes, Tanya

Contact Information:
Melissa Eagen
meagen@unmc.edu

Eligibility: https://clinicaltrials.gov/study/NCT07280013?term=NCT07280013&rank=1#participation-criteria

Summary
Primary: -To evaluate the safety and tolerability of cemsidomide in combination with elranatamab to determine the MTD or MAD Secondary: -To assess the antimyeloma activity of cemsidomide in combination with elranatamab -To evaluate the PK of cemsidomide and elranatamab in combination -To assess the immunogenicity of elranatamab when administered in combination with cemsidomide Exploratory: -To explore the relationship between PD biomarkers and clinical outcomes -To assess exposure-response relationships between cemsidomide and relevant markers of safety and efficacy